May 15, 2020 / 7:44 AM / 22 days ago

BRIEF-Scandion Oncology's Drug Som-001 Demonstrates Antibiotic Activity In Mouse Model Infected With MRSA Bacteria

May 15 (Reuters) - Scandion Oncology A/S:

* SCANDION ONCOLOGY’S DRUG SOM-001 DEMONSTRATES ANTIBIOTIC ACTIVITY IN A MOUSE MODEL INFECTED WITH MRSA BACTERIA

* SCANDION ONCOLOGY HAS RECEIVED POSITIVE RESULTS ON ANTIBIOTIC IN VIVO EFFECTS OF SOM-001 AND HAS DECIDED TO PROCEED WITH PRECLINICAL TESTING.

* MOREOVER, SOM-001 KILLS BACTERIA VIA A NOVEL MECHANISM OF ACTION AND FURTHER, RESISTANCE TO SOM-001 HAS NOT BEEN OBSERVED DURING IN VITRO CONDITIONS.

* BASED ON RESULTS OBTAINED SO FAR WITH SOM-001 IN ANTIBIOTIC RESISTANT BACTERIA, SCANDION ONCOLOGY HAS DECIDED TO PROCEED WITH PRECLINICAL TESTING OF SOM-001 AND ITS ANALOGUES Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below